Top 100 Outlook 2021: Medtechs Look To Build On Experiences Of Serving Global Markets In A Pandemic
If necessity is the mother of invention, then medtech firms know what is expected of them in 2021 ̶ how they achieve it might be less straightforward
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
You may also be interested in...
Medtech Insight spoke with Stephen Hahn, ex-FDA commissioner and CEO of Harbinger Health, who attended SXSW, about the firm’s blood-based cancer test in development.
After a year like no other for the global medtech industry, 2021 will present a different set of market challenges for device and diagnostic companies.
Industry attorneys predict that in the absence of the Supreme Court’s immediate response to arguments made in a key Affordable Care Act constitutionality case, that Congress will reaffirm the law.